ORION CORPORATION PRESS RELEASE 20 JUNE 2025 at 13.30 EEST CHMP recommends third indication for darolutamide for patients with advanced prostate cancer CHMP adopts positive opinion for the ...

ORION CORPORATION PRESS RELEASE 20 JUNE 2025 at 13.30 EEST CHMP recommends third indication for darolutamide for patients ...

The investigational MRI contrast agent, gadoquatrane, is designed to deliver effective imaging at a significantly reduced ...

Gilead Sciences, Inc. GILD obtained FDA approval for its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for the ...

A contract manufacturer and packager of drugs and personal care products is shutting down a plant this fall, causing 84 to ...

Every Cure—the overall winner of Newsweek's inaugural AI Impact Awards—is finding hidden disease cures on dusty drugstore ...

Explore the evolving RVO treatment landscape from anti-VEGF breakthroughs to pipeline innovations addressing unmet needs in efficacy, safety, and dosing burden. Retinal Vein Occlusion care is entering ...

Bayer BAYRY announced that it has submitted a new drug application (“NDA”) to the FDA seeking approval for its ...

Bayer AG Innovation Procurement has signed a multi-year extension with Scientist.com, becoming Bayer’s preferred global ...

The first successes of the turnaround are visible,' said Markus Manns, a portfolio manager at Union Investment in Frankfurt.

The drug formulation market is projected to expand from USD 1.7 trillion in 2025 to USD 2.8 trillion by 2035, growing at a ...

Bayer seeks US FDA approval for contrast agent, gadoquatrane for contrast-enhanced MRI of the CNS and other body regions: Berlin Wednesday, June 18, 2025, 09:00 Hrs [IST] Bayer an ...